---
sidebar_position: 14
---

# æ–‡ç» 14ï¼šCHAT-RT study: ChatGPT in radiation oncology-a survey on usage perception and impact among DEGRO members

**English Title**: CHAT-RT study: ChatGPT in radiation oncology-a survey on usage perception and impact among DEGRO members

**ä¸­æ–‡æ¨™é¡Œ**: CHAT-RT ç ”ç©¶ï¼šChatGPT åœ¨æ”¾å°„è…«ç˜¤å­¸ä¸­çš„æ‡‰ç”¨â€”â€”DEGRO æœƒå“¡çš„ä½¿ç”¨æ„ŸçŸ¥å’Œå½±éŸ¿èª¿æŸ¥
**PMID**: 40954471
**æœŸåˆŠ**: Radiation oncology
**è©•åˆ†**: 7
**æ‡‰ç”¨é ˜åŸŸ**: ä½é™¢/æ”¾ç™‚ç§‘
**DOI**: https://doi.org/10.1186/s13014-025-02721-9

---

## ğŸ“Œ ç¬¬ä¸€å¼µï¼šæ ¸å¿ƒè§€é»å¡

### ä¸»è¦ç™¼ç¾
æ”¾ç™‚é ˜åŸŸçš„ChatGPTæ‡‰ç”¨èª¿æŸ¥

### æ–‡ç»æ‘˜è¦ï¼ˆAbstractï¼‰
BACKGROUND: Radiation oncology is increasingly turning to Artificial Intelligence (AI) - and in particular Chat Generative pre-trained transformer (ChatGPT) - for decision support, patient education, and workflow efficiency. Despite promising gains, questions about accuracy, General Data Protection Regulation (GDPR)-compliance and ethical use persist, especially in high-stakes cancer care. To clarify real-world attitudes and practices, we surveyed members of the German Society of Radiation Oncology (DEGRO) on their use, perceptions, and concerns regarding ChatGPT across clinical, research, communication, and administrative tasks. METHODS: An anonymous online survey was implemented via LimeSurvey platform and distributed to all members of the DEGRO in Germany, Austria, and Switzerland between April and June 2024. The 40-item questionnaire-covering demographics, radiotherapy experience, and ChatGPT's clinical, research, communication, and administrative applications-was developed through a narrative literature review, ChatGPT-assisted drafting, back-translation, expert validation, and pilot testing. Fully completed responses were used for descriptive statistics and analysis. RESULTS: Of 213 respondents, 159 fully completed the survey. Participants were predominantly based in Germany (92.5%), worked in university hospitals (74.2%), and identified as radiation oncologists (54.7%), with a broad range of radiotherapy experience (&lt;â€‰1 year: 7.5%; &gt;15 years: 24.5%). Awareness of ChatGPT was high (94.9%), yet actual use varied: 32.1% never used it, while 35.2% employed it regularly for administrative tasks and 30.2% for manuscript drafting. Mid-career clinicians (6-10 years' experience) showed the greatest enthusiasm-44% agreed it saves time and 72% planned further integration-though all career stages (71.7% overall) expressed strong interest in formal training. Satisfaction was highest for administrative (94.6%) and manuscript support (91.7%) but lower for technical queries (66.7%). Major concerns included misinformation (69.2%), erosion of critical thinking (57.9%), and data-privacy risks (57.2%). CONCLUSION: Our survey demonstrates high awareness and adoption of ChatGPT for administrative and educational tasks, alongside more cautious use in clinical decision-making. Widespread concerns about misinformation, critical-thinking erosion, and data privacy-especially among early- and mid-career clinicians-underscore the need for targeted AI training, rigorous validation, and transparent governance to ensure safe, effective integration into patient care.

### ä¸­æ–‡æ‘˜è¦
**èƒŒæ™¯**ï¼šæ”¾å°„è…«ç˜¤å­¸æ—¥ç›Šè½‰å‘äººå·¥æ™ºèƒ½ï¼ˆAIï¼‰â€”â€”ç‰¹åˆ¥æ˜¯å°è©±å¼ç”Ÿæˆé è¨“ç·´è½‰æ›å™¨ï¼ˆChatGPTï¼‰â€”â€”ä»¥æä¾›æ±ºç­–æ”¯æŒã€æ‚£è€…æ•™è‚²å’Œå·¥ä½œæµç¨‹æ•ˆç‡ã€‚å„˜ç®¡æœ‰ä»¤äººé¼“èˆçš„é€²å±•ï¼Œä½†é—œæ–¼æº–ç¢ºæ€§ã€ä¸€èˆ¬è³‡æ–™ä¿è­·è¦ç¯„ï¼ˆGDPRï¼‰åˆè¦æ€§å’Œå€«ç†ä½¿ç”¨çš„å•é¡Œä»ç„¶å­˜åœ¨ï¼Œç‰¹åˆ¥æ˜¯åœ¨é«˜é¢¨éšªçš„ç™Œç—‡ç…§è­·ä¸­ã€‚ç‚ºäº†é‡æ¸…çœŸå¯¦ä¸–ç•Œçš„æ…‹åº¦å’Œå¯¦è¸ï¼Œæˆ‘å€‘èª¿æŸ¥äº†å¾·åœ‹æ”¾å°„è…«ç˜¤å­¸æœƒï¼ˆDEGROï¼‰æœƒå“¡å°å…¶ä½¿ç”¨ã€èªçŸ¥å’Œ ChatGPT åœ¨è‡¨åºŠã€ç ”ç©¶ã€æºé€šå’Œè¡Œæ”¿ä»»å‹™ä¸­çš„é—œæ³¨ã€‚**æ–¹æ³•**ï¼šåœ¨ 2024 å¹´ 4 æœˆè‡³ 6 æœˆæœŸé–“ï¼Œé€é LimeSurvey å¹³å°å‘å¾·åœ‹ã€å¥§åœ°åˆ©å’Œç‘å£«çš„æ‰€æœ‰ DEGRO æœƒå“¡ç™¼æ”¾äº†ä¸€ä»½åŒ¿åç·šä¸Šå•å·ã€‚è©² 40 é …å•å·â€”â€”æ¶µè“‹äººå£çµ±è¨ˆå­¸ã€æ”¾å°„æ²»ç™‚ç¶“é©—ï¼Œä»¥åŠ ChatGPT çš„è‡¨åºŠã€ç ”ç©¶ã€æºé€šå’Œè¡Œæ”¿æ‡‰ç”¨â€”â€”æ˜¯é€éæ•˜äº‹æ€§æ–‡ç»å›é¡§ã€ChatGPT å”åŠ©èµ·è‰ã€å›è­¯ã€å°ˆå®¶é©—è­‰å’Œè©¦é©—æ¸¬è©¦è€Œé–‹ç™¼çš„ã€‚å®Œå…¨å®Œæˆçš„å›æ‡‰ç”¨æ–¼æè¿°æ€§çµ±è¨ˆå’Œåˆ†æã€‚**çµæœ**ï¼šåœ¨ 213 åå—è¨ªè€…ä¸­ï¼Œ159 äººå®Œå…¨å®Œæˆäº†å•å·ã€‚åƒèˆ‡è€…ä¸»è¦ä¾†è‡ªå¾·åœ‹ï¼ˆ92.5%ï¼‰ï¼Œåœ¨å¤§å­¸é†«é™¢å·¥ä½œï¼ˆ74.2%ï¼‰ï¼Œä¸¦èªå®šç‚ºæ”¾å°„è…«ç˜¤ç§‘é†«å¸«ï¼ˆ54.7%ï¼‰ï¼Œå…·æœ‰å»£æ³›çš„æ”¾å°„æ²»ç™‚ç¶“é©—ï¼ˆ< 1 å¹´ï¼š7.5%ï¼›>15 å¹´ï¼š24.5%ï¼‰ã€‚å° ChatGPT çš„èªè­˜å¾ˆé«˜ï¼ˆ94.9%ï¼‰ï¼Œä½†å¯¦éš›ä½¿ç”¨å„ç•°ï¼š32.1% å¾æœªä½¿ç”¨éå®ƒï¼Œè€Œ 35.2% ç¶“å¸¸å°‡å…¶ç”¨æ–¼è¡Œæ”¿ä»»å‹™ï¼Œ30.2% ç”¨æ–¼æ‰‹ç¨¿èµ·è‰ã€‚ä¸­æœŸè·æ¥­è‡¨åºŠé†«å¸«ï¼ˆ6-10 å¹´ç¶“é©—ï¼‰è¡¨ç¾å‡ºæœ€å¤§çš„ç†±æƒ…â€”â€”44% åŒæ„å®ƒç¯€çœæ™‚é–“ï¼Œ72% è¨ˆç•«é€²ä¸€æ­¥æ•´åˆâ€”â€”å„˜ç®¡æ‰€æœ‰è·æ¥­éšæ®µï¼ˆæ•´é«” 71.7%ï¼‰éƒ½è¡¨é”äº†å°æ­£å¼åŸ¹è¨“çš„å¼·çƒˆèˆˆè¶£ã€‚å°è¡Œæ”¿ï¼ˆ94.6%ï¼‰å’Œæ‰‹ç¨¿æ”¯æŒï¼ˆ91.7%ï¼‰çš„æ»¿æ„åº¦æœ€é«˜ï¼Œä½†å°æŠ€è¡“æŸ¥è©¢ï¼ˆ66.7%ï¼‰è¼ƒä½ã€‚ä¸»è¦é—œæ³¨åŒ…æ‹¬éŒ¯èª¤è³‡è¨Šï¼ˆ69.2%ï¼‰ã€æ‰¹åˆ¤æ€§æ€è€ƒçš„ä¾µè•ï¼ˆ57.9%ï¼‰å’Œè³‡æ–™éš±ç§é¢¨éšªï¼ˆ57.2%ï¼‰ã€‚**çµè«–**ï¼šæˆ‘å€‘çš„èª¿æŸ¥é¡¯ç¤ºï¼Œå° ChatGPT åœ¨è¡Œæ”¿å’Œæ•™è‚²ä»»å‹™ä¸­çš„èªè­˜å’Œæ¡ç”¨åº¦å¾ˆé«˜ï¼ŒåŒæ™‚åœ¨è‡¨åºŠæ±ºç­–ä¸­ä½¿ç”¨æ›´ç‚ºè¬¹æ…ã€‚å°éŒ¯èª¤è³‡è¨Šã€æ‰¹åˆ¤æ€§æ€è€ƒä¾µè•å’Œè³‡æ–™éš±ç§çš„å»£æ³›é—œæ³¨â€”â€”ç‰¹åˆ¥æ˜¯åœ¨æ—©æœŸå’Œä¸­æœŸè·æ¥­è‡¨åºŠé†«å¸«ä¸­â€”â€”å¼·èª¿äº†éœ€è¦é‡å°æ€§çš„ AI åŸ¹è¨“ã€åš´æ ¼é©—è­‰å’Œé€æ˜æ²»ç†ï¼Œä»¥ç¢ºä¿å®‰å…¨æœ‰æ•ˆåœ°æ•´åˆè‡³æ‚£è€…ç…§è­·ä¸­ã€‚

### é—œéµæ•¸æ“š
- **ç ”ç©¶é¡å‹**: æœªåˆ†é¡
- **åœ‹å®¶/åœ°å€**: å¾…æŸ¥
- **ç™¼è¡¨å¹´ä»½**: å¾…æŸ¥
- **ROI æ•¸å€¼**: ç„¡æ•¸å€¼

### æ ¸å¿ƒå‰µæ–°é»
æœ¬ç ”ç©¶çš„ä¸»è¦å‰µæ–°åœ¨æ–¼ï¼šæ”¾ç™‚é ˜åŸŸçš„ChatGPTæ‡‰ç”¨èª¿æŸ¥

---

## âœï¸ ç¬¬äºŒå¼µï¼šParaphrase å¡

### ç ”ç©¶ç›®çš„èˆ‡æ–¹æ³•
æœ¬ç ”ç©¶èšç„¦æ–¼ä½é™¢/æ”¾ç™‚ç§‘é ˜åŸŸï¼Œæ—¨åœ¨æ¢è¨ AI æŠ€è¡“åœ¨é†«ç™‚å ´æ™¯ä¸­çš„æ‡‰ç”¨ã€‚

### ä¸»è¦è²¢ç»
ç ”ç©¶æå‡ºäº†æ”¾ç™‚é ˜åŸŸçš„ChatGPTæ‡‰ç”¨èª¿æŸ¥ï¼Œç‚ºè‡¨åºŠå¯¦è¸æä¾›äº†æ–°çš„è§£æ±ºæ–¹æ¡ˆã€‚

### æŠ€è¡“ç‰¹é»
- æ‡‰ç”¨å ´æ™¯ï¼šä½é™¢/æ”¾ç™‚ç§‘
- å‰µæ–°ç¨‹åº¦ï¼šè©•åˆ† 7/10
- æœŸåˆŠå½±éŸ¿ï¼šç™¼è¡¨æ–¼ Radiation oncology

---

## â“ ç¬¬ä¸‰å¼µï¼šå•ç­”å¡

### Q1: é€™é …ç ”ç©¶è§£æ±ºäº†ä»€éº¼å•é¡Œï¼Ÿ
A: æœ¬ç ”ç©¶é‡å°ä½é™¢/æ”¾ç™‚ç§‘é ˜åŸŸçš„æŒ‘æˆ°ï¼Œæå‡ºäº†åŸºæ–¼ AI çš„è§£æ±ºæ–¹æ¡ˆã€‚

### Q2: æ¡ç”¨äº†ä»€éº¼æŠ€è¡“æ–¹æ³•ï¼Ÿ
A: æ”¾ç™‚é ˜åŸŸçš„ChatGPTæ‡‰ç”¨èª¿æŸ¥

### Q3: ç ”ç©¶çš„ä¸»è¦æˆæœæ˜¯ä»€éº¼ï¼Ÿ
A: ç ”ç©¶ç²å¾—äº† 7 åˆ†çš„å°ˆå®¶è©•åˆ†ï¼Œè­‰æ˜äº†å…¶åœ¨ä½é™¢/æ”¾ç™‚ç§‘é ˜åŸŸçš„æ‡‰ç”¨åƒ¹å€¼ã€‚

### Q4: æœ‰å“ªäº›å¯¦éš›æ‡‰ç”¨å ´æ™¯ï¼Ÿ
A: ä¸»è¦æ‡‰ç”¨æ–¼ä½é™¢/æ”¾ç™‚ç§‘ï¼Œå¯ç”¨æ–¼æ”¹å–„é†«ç™‚æœå‹™å“è³ªå’Œæ•ˆç‡ã€‚

---

## ğŸ¤” ç¬¬å››å¼µï¼šä¾‹å¤–å¡

### æ½›åœ¨é™åˆ¶
1. **ç ”ç©¶ç¯„åœ**: ç ”ç©¶è©•åˆ†ç‚º 7/10ï¼Œå¯èƒ½å­˜åœ¨æ”¹é€²ç©ºé–“
2. **åœ°å€å·®ç•°**: ç ”ç©¶ä¾†è‡ªå¾…æŸ¥ï¼Œå…¶ä»–åœ°å€é©ç”¨æ€§éœ€é©—è­‰
3. **ROI æ•¸æ“š**: ç„¡æ•¸å€¼ï¼Œç¶“æ¿Ÿæ•ˆç›Šè©•ä¼°å¯èƒ½ä¸å®Œæ•´

### éœ€è¦é€²ä¸€æ­¥æ¢è¨çš„å•é¡Œ
1. è©²æŠ€è¡“åœ¨ä¸åŒè¦æ¨¡é†«é™¢çš„é©ç”¨æ€§å¦‚ä½•ï¼Ÿ
2. é•·æœŸä½¿ç”¨çš„æ•ˆæœå’Œç©©å®šæ€§æ˜¯å¦ç¶“éé©—è­‰ï¼Ÿ
3. èˆ‡ç¾æœ‰ç³»çµ±æ•´åˆæ™‚å¯èƒ½é¢è‡¨å“ªäº›æŒ‘æˆ°ï¼Ÿ

### æ‰¹åˆ¤æ€§æ€è€ƒ
- **æŠ€è¡“æˆç†Ÿåº¦**: éœ€è¦è©•ä¼°å¾ç ”ç©¶åˆ°å¯¦éš›éƒ¨ç½²çš„è·é›¢
- **æˆæœ¬æ•ˆç›Š**: ç„¡æ•¸å€¼ï¼Œéœ€è¦æ›´è©³ç´°çš„ç¶“æ¿Ÿåˆ†æ
- **å€«ç†è€ƒé‡**: AI åœ¨ä½é™¢/æ”¾ç™‚ç§‘æ‡‰ç”¨æ™‚çš„å€«ç†å’Œéš±ç§å•é¡Œ
- **å¯æ¨å»£æ€§**: ç ”ç©¶çµæœåœ¨å…¶ä»–é†«ç™‚å ´æ™¯çš„é©ç”¨æ€§

---

## ğŸ“š åƒè€ƒè³‡è¨Š
- **PMID**: [40954471](https://pubmed.ncbi.nlm.nih.gov/40954471/)
- **DOI**: https://doi.org/10.1186/s13014-025-02721-9
- **æœŸåˆŠ**: Radiation oncology
